- Home
- XBP vs CUE Comparison
XBP vs CUE Comparison
Compare XBP & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBP
- CUE
- Stock Information
- Founded
- XBP 2020
- CUE 2014
- Country
- XBP United States
- CUE United States
- Employees
- XBP N/A
- CUE N/A
- Industry
- XBP Business Services
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- XBP Consumer Discretionary
- CUE Health Care
- Exchange
- XBP Nasdaq
- CUE Nasdaq
- Market Cap
- XBP 71.0M
- CUE 59.5M
- IPO Year
- XBP N/A
- CUE 2018
- Fundamental
- Price
- XBP $0.95
- CUE $0.77
- Analyst Decision
- XBP
- CUE Strong Buy
- Analyst Count
- XBP 0
- CUE 2
- Target Price
- XBP N/A
- CUE $3.00
- AVG Volume (30 Days)
- XBP 502.8K
- CUE 127.4K
- Earning Date
- XBP 11-11-2025
- CUE 11-13-2025
- Dividend Yield
- XBP N/A
- CUE N/A
- EPS Growth
- XBP N/A
- CUE N/A
- EPS
- XBP N/A
- CUE N/A
- Revenue
- XBP $148,332,000.00
- CUE $8,286,000.00
- Revenue This Year
- XBP N/A
- CUE N/A
- Revenue Next Year
- XBP N/A
- CUE $10.19
- P/E Ratio
- XBP N/A
- CUE N/A
- Revenue Growth
- XBP 0.23
- CUE N/A
- 52 Week Low
- XBP $0.42
- CUE $0.45
- 52 Week High
- XBP $2.56
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- XBP 64.44
- CUE 51.01
- Support Level
- XBP $0.80
- CUE N/A
- Resistance Level
- XBP $1.01
- CUE $0.79
- Average True Range (ATR)
- XBP 0.10
- CUE 0.03
- MACD
- XBP 0.05
- CUE -0.03
- Stochastic Oscillator
- XBP 86.13
- CUE 91.08
About XBP XBP Europe Holdings Inc.
XBP Global Holdings Inc is a multinational leader in business process automation, serving over 2,500 clients-including more than 30 Fortune 100 companies. Its proprietary software and deep domain expertise position it as a trusted technology and services partner. With cloud-based solutions and a global footprint, XBP Global delivers measurable value, improves advances digital transformation, improves market-wide liquidity by expediting payments, and promotes sustainable business practices.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.